Ms. Melonie Devi Sanassy is a pharmacist who is specialized in Oncology in New York, New York. Patients can reach her at 300 E 66th St, New York or contact her on 917-294-1343. Active license number of Ms. Melonie Devi Sanassy is 065492 for Oncology in New York. Ms. Melonie Devi Sanassy is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Ms. Melonie Devi Sanassy speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Ms. Melonie Devi Sanassy
Specialization:
Oncology
Gender:
Female
Location:
300 E 66th St, New York, New York, 10065-6800
Phone:
917-294-1343
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Ms. Melonie Devi Sanassy are as mentioned below.
NPI Number:
1043867518
NPI Enumeration Date:
20 Aug, 2019
NPI Last Update On:
20 Aug, 2019
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Ms. Melonie Devi Sanassy are as mentioned below.
Specialization
License Number
State
Status
Oncology
065492
New York
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
2151 27th St Apt D2, Astoria, New York
Zip:
11105-3045
Phone Number:
917-294-1343
Fax Number:
--
Patients can reach Ms. Melonie Devi Sanassy at 300 E 66th St, New York, New York or can call on phone at 917-294-1343.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.